|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HSD11B1L |
Gene summary for HSD11B1L |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HSD11B1L | Gene ID | 374875 |
| Gene name | hydroxysteroid 11-beta dehydrogenase 1 like | |
| Gene Alias | 11-DH3 | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A087WWR3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 374875 | HSD11B1L | P27T-E | Human | Esophagus | ESCC | 1.12e-29 | 4.73e-01 | 0.1055 |
| 374875 | HSD11B1L | P28T-E | Human | Esophagus | ESCC | 1.91e-39 | 6.13e-01 | 0.1149 |
| 374875 | HSD11B1L | P30T-E | Human | Esophagus | ESCC | 1.56e-12 | 4.24e-01 | 0.137 |
| 374875 | HSD11B1L | P31T-E | Human | Esophagus | ESCC | 6.71e-05 | 3.56e-02 | 0.1251 |
| 374875 | HSD11B1L | P32T-E | Human | Esophagus | ESCC | 1.79e-08 | 1.09e-01 | 0.1666 |
| 374875 | HSD11B1L | P36T-E | Human | Esophagus | ESCC | 9.86e-13 | 3.55e-01 | 0.1187 |
| 374875 | HSD11B1L | P38T-E | Human | Esophagus | ESCC | 2.58e-10 | 3.46e-01 | 0.127 |
| 374875 | HSD11B1L | P39T-E | Human | Esophagus | ESCC | 1.11e-06 | 9.38e-02 | 0.0894 |
| 374875 | HSD11B1L | P40T-E | Human | Esophagus | ESCC | 5.68e-07 | 1.87e-01 | 0.109 |
| 374875 | HSD11B1L | P42T-E | Human | Esophagus | ESCC | 7.53e-19 | 4.38e-01 | 0.1175 |
| 374875 | HSD11B1L | P44T-E | Human | Esophagus | ESCC | 6.29e-05 | 1.39e-01 | 0.1096 |
| 374875 | HSD11B1L | P47T-E | Human | Esophagus | ESCC | 2.63e-05 | 1.05e-01 | 0.1067 |
| 374875 | HSD11B1L | P48T-E | Human | Esophagus | ESCC | 5.64e-07 | 4.76e-02 | 0.0959 |
| 374875 | HSD11B1L | P52T-E | Human | Esophagus | ESCC | 1.48e-08 | 5.78e-02 | 0.1555 |
| 374875 | HSD11B1L | P56T-E | Human | Esophagus | ESCC | 6.66e-05 | 3.49e-01 | 0.1613 |
| 374875 | HSD11B1L | P57T-E | Human | Esophagus | ESCC | 3.82e-24 | 1.78e-01 | 0.0926 |
| 374875 | HSD11B1L | P62T-E | Human | Esophagus | ESCC | 1.10e-07 | 1.47e-01 | 0.1302 |
| 374875 | HSD11B1L | P74T-E | Human | Esophagus | ESCC | 8.25e-13 | 2.60e-01 | 0.1479 |
| 374875 | HSD11B1L | P75T-E | Human | Esophagus | ESCC | 1.91e-05 | 5.94e-02 | 0.1125 |
| 374875 | HSD11B1L | P76T-E | Human | Esophagus | ESCC | 4.19e-12 | 1.49e-01 | 0.1207 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HSD11B1L | SNV | Missense_Mutation | novel | c.175N>A | p.Leu59Met | p.L59M | protein_coding | tolerated(0.13) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| HSD11B1L | deletion | Frame_Shift_Del | novel | c.168delN | p.Ala58ProfsTer24 | p.A58Pfs*24 | protein_coding | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |||
| HSD11B1L | SNV | Missense_Mutation | novel | c.352N>T | p.Gly118Trp | p.G118W | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HSD11B1L | SNV | Missense_Mutation | novel | c.453G>C | p.Lys151Asn | p.K151N | protein_coding | tolerated(0.21) | possibly_damaging(0.875) | TCGA-AX-A3G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HSD11B1L | SNV | Missense_Mutation | novel | c.746A>G | p.Asn249Ser | p.N249S | protein_coding | deleterious(0.02) | possibly_damaging(0.46) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| HSD11B1L | SNV | Missense_Mutation | novel | c.584N>T | p.Arg195Leu | p.R195L | protein_coding | tolerated(0.95) | benign(0.001) | TCGA-CV-7238-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HSD11B1L | SNV | Missense_Mutation | c.374N>T | p.Ala125Val | p.A125V | protein_coding | deleterious(0) | probably_damaging(0.911) | TCGA-BR-7959-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | CR | ||
| HSD11B1L | deletion | Frame_Shift_Del | novel | c.168delN | p.Ala58ProfsTer24 | p.A58Pfs*24 | protein_coding | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |